Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06738303 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Study acronym: CATCH-177
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later Dec 2026 → Feb 20, 2028
See other at-risk trials from Case Comprehensive Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 2026 to Feb 20, 2028
    • Study completion pushed from Dec 2026 to Dec 1, 2029
  2. Eligibility criteria shortened, about 21 words
  3. Eligibility criteria expanded, about 37 wordsv7
  4. Start date changed from estimate of Jul 2025 to Jul 14, 2025v6
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: May 2025 to Jul 2025v4
  2. Start date: Mar 15, 2025 to May 2025v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.
Trial Details
NCT Number NCT06738303
Lead Sponsor Case Comprehensive Cancer Center
Conditions
(from sponsor)		 Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov